Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis

NCT03120949 is registered in ClinicalTrials.gov with R-Pharm International, LLC as lead sponsor.

NCT NCT03120949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03120949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Lead sponsor
R-Pharm International, LLC
Phase
Phase 3
Overall status
Completed
Start date
July 4, 2017
Completion date
September 1, 2021
Enrollment
2,106 (actual)
Sites
239

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis